-
High-Throughput Discovery of M. tuberculosis DHFR
2026-08-26
Santa Maria et al. developed a data-integration framework that connects whole-cell antibacterial phenotypes with high-throughput protein-binding data and machine learning. The approach recapitulated known mechanisms and prospectively identified nanomolar Mycobacterium tuberculosis dihydrofolate reductase inhibitors, illustrating a practical route for target deconvolution and antibacterial research.
-
Toremifene Citrate: From ER Binding to Assay Design
2026-08-25
Toremifene Citrate is an oral selective estrogen receptor modulator with applications spanning receptor pharmacology and breast cancer research. This guide translates comparative clinical evidence into practical decisions for pathway assays, concentration design, controls, and data interpretation.
-
Oligomycin A Workflow for Mitochondrial Bioenergetics
2026-08-25
Oligomycin A provides a targeted way to separate ATP synthase-dependent respiration from broader mitochondrial stress. This practical guide connects acute oxygen-consumption assays with ATP depletion, ROS, apoptosis, and sodium-driven energy failure models for more informative cancer metabolism research.
-
CB-5083 in Reliable p97 Inhibitor Assays
2026-08-24
Learn how CB-5083 (SKU B6032) can improve the design and interpretation of cell viability, proliferation, and cytotoxicity experiments involving p97 inhibition. This scenario-based guide connects biochemical potency, solvent handling, orthogonal readouts, and vendor-selection criteria to reproducible laboratory workflows.
-
Lactate–GPR81–RAC1 Control of Glucose Uptake
2026-08-23
The reference study identifies lactate as an insulin-independent signal that improves glucose disposal through a GPR81–FARP1–RAC1–GLUT4 pathway in skeletal muscle. Its genetic, pharmacological, exercise, and human-association evidence positions GPR81 signaling as a distinct mechanism for metabolic control while providing a framework for testing RAC1-dependent glucose transport.
-
PCN, Hippocampal CYP, and Phenytoin Neurotoxicity
2026-08-22
A 2025 study identifies an unexpected tissue-specific action of Pregnenolone-16α-carbonitrile: it induces CYP3A11 and CYP2B10 in mouse liver but suppresses these enzymes in the hippocampus. The hippocampal effect reduced phenytoin-associated neuronal injury through glucocorticoid receptor signaling rather than the canonical PXR pathway, highlighting the importance of organ-specific mechanistic analysis.
-
DAPT (GSI-IX): Reliable Notch Assay Design
2026-08-22
This scenario-led guide explains how DAPT (GSI-IX), SKU A8200, can be integrated into viability, proliferation, and cytotoxicity workflows without confusing pathway modulation with nonspecific cell damage. It connects product-reported potency, formulation, storage, and assay benchmarks with practical controls for Alzheimer's disease research, cancer research, and Notch signaling studies.
-
Cdc42 as a Translational Control Point in Fibrosis
2026-08-21
Cdc42 sits at the intersection of cytoskeletal remodeling, cell motility, neuronal architecture, and fibroblast activation. This thought-leadership analysis positions ZCL278 as a selective Cdc42 inhibitor for testing whether precise Cdc42 perturbation can connect cellular phenotypes to the Cdc42–PKCζ–GSK-3β–β-catenin axis implicated in kidney fibrosis.
-
NSC-23766 as a Rac1 Metabolic Probe
2026-08-20
NSC-23766 is a Rac GTPase inhibitor with a distinctive opportunity in metabolic research: testing whether Rac1 is required for lactate-driven, insulin-independent glucose uptake. This article connects the compound’s established cellular phenotypes with the GPR81/FARP1/GLUT4 mechanism while emphasizing assay controls, interpretation, and translational limits.
-
ZCL278: Selective Cdc42 Inhibitor Guide
2026-08-20
ZCL278 is a selective Cdc42 inhibitor for probing Cdc42-dependent signaling, cell motility, Golgi organization, and neuronal morphology. Product data support biochemical binding and cell-based effects, while a separate peer-reviewed study establishes Cdc42 as a fibrosis-relevant target without demonstrating that ZCL278 itself treats kidney fibrosis.
-
Lactate–GPR81–FARP1 Drives Insulin-Independent Uptake
2026-08-19
A 2026 Cell Research study identifies L-lactate as an insulin-independent regulator of skeletal-muscle glucose uptake through the GPR81/FARP1/RAC1/GLUT4 axis. Its genetic, pharmacological, exercise, and human association data connect lactate production with glucose control while defining a potential route for improving glycemia beyond canonical insulin–AKT signaling.
-
Clozapine Beyond Receptor Binding: A Translational Playbook
2026-08-19
A thought-leadership guide for using Clozapine to connect receptor pharmacology, ERK1/2 signaling activation, prefrontal-cortex biology, and safety-oriented assay design in schizophrenia research.
-
Pseudo-UTP for mRNA Synthesis Workflows
2026-08-18
Pseudo-UTP enables pseudouridine-containing RNA workflows designed for stronger persistence, translation, and tolerability. This guide connects practical in vitro transcription optimization with personalized tumor-vaccine delivery research, including OMV-based antigen display, quality control, and troubleshooting.
-
β-Blockers and Hematopoietic Regeneration after HCT
2026-08-18
The reference study shows that β-adrenergic receptor selectivity is critical after hematopoietic cell transplantation: nonselective blockade impaired marrow regeneration in mice and was associated with delayed platelet engraftment and lower survival after allogeneic transplantation in humans, whereas β1-selective blockade did not produce the same pattern. Its translational value lies in linking peripheral-nerve signaling, transplant context, posttransplant chemotherapy, and cell dose to engraftment outcomes.
-
PEGylated Iron Oxide Nanoparticles in Liver Cells
2026-08-17
A 2026 ACS Nano study combines 99mTc-based SPECT/CT with primary liver-cell assays to show how iron oxide nanoparticle size and PEG chain length jointly control hepatic distribution. Its most consequential finding is that hepatocytes and hepatic stellate cells can dominate cellular uptake, challenging the assumption that Kupffer cells are always the principal hepatic sink and providing a more precise framework for nanomedicine design.